JUNS Earnings — Jupiter Neurosciences, Inc. Common Stock Post-ER Performance | BigEarnings
JUNS — Jupiter Neurosciences, Inc. Common Stock
XNAS
Price$0.26
Market Cap$11.3M
P/E—
52W Range$0.17 – $3.33
Next Earnings2026-08-18
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
